Comparison Overview

Pharmaceutical Marketing

VS

Uitgeverij Deviant

Pharmaceutical Marketing

US
Last Update: 2025-11-28
Between 750 and 799

PMGroup Worldwide Limited A member of the Datateam Business Media group, PMGroup has grown from small beginnings over 20 years ago to become a leading international multi-channel media group in the pharmaceutical industry. With a portfolio spanning print, digital and events, PMGroup is proud to support the healthcare and life sciences sectors.

NAICS: 511
NAICS Definition: Publishing Industries (except Internet)
Employees: 139
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Uitgeverij Deviant

Zuidsingel 13, Amersfoort, NL, 3811 HA
Last Update: 2025-11-26

Uitgeverij Deviant is een educatieve uitgeverij die methodes burgerschap, Engels, Nederlands en rekenen ontwikkelt voor het mbo, vo en praktijkonderwijs. De methodes van Uitgeverij Deviant sluiten uitstekend aan bij de verschillende doelgroepen en niveaus binnen deze onderwijssoorten. Uitgeverij Deviant gaat ervan uit dat een combinatie van boeken en digitale leermiddelen het hoogste rendement oplevert. Daarom ontwikkelt Uitgeverij Deviant naast boeken ook zelf digitale leermiddelen, zoals online oefen- en toetsprogramma’s, niveautesten en serious games.

NAICS: 511
NAICS Definition: Publishing Industries (except Internet)
Employees: 47
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
Pharmaceutical Marketing
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/uitgeverij-deviant.jpeg
Uitgeverij Deviant
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Pharmaceutical Marketing
100%
Compliance Rate
0/4 Standards Verified
Uitgeverij Deviant
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for Pharmaceutical Marketing in 2025.

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for Uitgeverij Deviant in 2025.

Incident History — Pharmaceutical Marketing (X = Date, Y = Severity)

Pharmaceutical Marketing cyber incidents detection timeline including parent company and subsidiaries

Incident History — Uitgeverij Deviant (X = Date, Y = Severity)

Uitgeverij Deviant cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/defaultcompany.jpeg
Pharmaceutical Marketing
Incidents

No Incident

https://images.rankiteo.com/companyimages/uitgeverij-deviant.jpeg
Uitgeverij Deviant
Incidents

No Incident

FAQ

Pharmaceutical Marketing company demonstrates a stronger AI Cybersecurity Score compared to Uitgeverij Deviant company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Uitgeverij Deviant company has disclosed a higher number of cyber incidents compared to Pharmaceutical Marketing company.

In the current year, Uitgeverij Deviant company and Pharmaceutical Marketing company have not reported any cyber incidents.

Neither Uitgeverij Deviant company nor Pharmaceutical Marketing company has reported experiencing a ransomware attack publicly.

Neither Uitgeverij Deviant company nor Pharmaceutical Marketing company has reported experiencing a data breach publicly.

Neither Uitgeverij Deviant company nor Pharmaceutical Marketing company has reported experiencing targeted cyberattacks publicly.

Neither Pharmaceutical Marketing company nor Uitgeverij Deviant company has reported experiencing or disclosing vulnerabilities publicly.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Pharmaceutical Marketing company nor Uitgeverij Deviant company has publicly disclosed detailed information about the number of their subsidiaries.

Pharmaceutical Marketing company employs more people globally than Uitgeverij Deviant company, reflecting its scale as a Book and Periodical Publishing.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds SOC 2 Type 1 certification.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds SOC 2 Type 2 certification.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds ISO 27001 certification.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds PCI DSS certification.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds HIPAA certification.

Neither Pharmaceutical Marketing nor Uitgeverij Deviant holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

ThingsBoard in versions prior to v4.2.1 allows an authenticated user to upload malicious SVG images via the "Image Gallery", leading to a Stored Cross-Site Scripting (XSS) vulnerability. The exploit can be triggered when any user accesses the public API endpoint of the malicious SVG images, or if the malicious images are embedded in an `iframe` element, during a widget creation, deployed to any page of the platform (e.g., dashboards), and accessed during normal operations. The vulnerability resides in the `ImageController`, which fails to restrict the execution of JavaScript code when an image is loaded by the user's browser. This vulnerability can lead to the execution of malicious code in the context of other users' sessions, potentially compromising their accounts and allowing unauthorized actions.

Risk Information
cvss4
Base: 6.2
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:N/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to to verify that the token used during the code exchange originates from the same authentication flow, which allows an authenticated user to perform account takeover via a specially crafted email address used when switching authentication methods and sending a request to the /users/login/sso/code-exchange endpoint. The vulnerability requires ExperimentalEnableAuthenticationTransfer to be enabled (default: enabled) and RequireEmailVerification to be disabled (default: disabled).

Risk Information
cvss3
Base: 9.9
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to sanitize team email addresses to be visible only to Team Admins, which allows any authenticated user to view team email addresses via the GET /api/v4/channels/{channel_id}/common_teams endpoint

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

Exposure of email service credentials to users without administrative rights in Devolutions Server.This issue affects Devolutions Server: before 2025.2.21, before 2025.3.9.

Description

Exposure of credentials in unintended requests in Devolutions Server.This issue affects Server: through 2025.2.20, through 2025.3.8.